US Oncology Research Affiliated Investigators participate in studies that will be presented at the 2012 American Society of Hematology Annual Meeting and Exposition

Leading investigators affiliated with US Oncology Research involved in eight oral clinical study presentations and eight posters

The Woodlands, Texas (Dec. 6, 2012) — Eleven leading investigators affiliated with US Oncology Research participated in nearly 20 studies that will be presented at the 54th American Society of Hematology (ASH) Annual Meeting and Exposition in Atlanta, Ga. at the Georgia World Congress Center. ASH will take place Dec. 8-11 and is an educational and scientific program that helps Hematology professionals stay up-to-date on the latest research, therapies, and tools needed to be successful in their field.

John Burke, M.D., medical oncologist and hematologist with Rocky Mountain Cancer Centers, an affiliate of US Oncology Research, is presenting a study titled, “Differences in Quality of Life Between Bendamustine Plus Rituximab Compared with Standard First-Line Treatments in Patients with Previously Untreated Advanced Indolent Non-Hodgkin’s Lymphoma or Mantle Cell Lymphoma,” on Dec. 9 at 5:30pm. This study compared the efficacy and safety of the combination of bendamustine and rituximab with standard therapy in the first-line treatment of patients with indolent non-Hodgkin’s lymphoma or mantle cell lymphoma. Kathryn Kolibaba, M.D., medical oncologist and hematologist with Compass Oncology, an affiliate of US Oncology Research, also participated in this study.

In addition to Dr. Burke’s presentation, 18 other US Oncology Research affiliated studies will be featured as oral presentations, posters or publications at this year’s meeting. Affiliated physicians Robert Rifkin, M.D., hematologist with Rocky Mountain Cancer Centers, as well as Hakan Kaya, M.D., medical oncologist and hematologist with Cancer Care Northwest, will also participate in Case Discussions on Dec. 7.

A full list of US Oncology Research affiliated studies on display at the ASH Annual Meeting is below. For more information or to interview an investigator, contact US Oncology Research Public Relations Manager, Claire Crye at 281-863-6783.

Oral Presentations:

1. Efficacy, Hematologic Effects, and Dose of Ruxolitinib in Myelofibrosis Patients with Low Starting Platelet Counts (50–100 x 10^9/L): A Comparison to Patients with Normal or High Starting Platelet Counts

2. The Bruton’s Tyrosine Kinase (BTK) Inhibitor Ibrutinib (PCI-32765) Promotes High Response Rate, Durable Remissions, and Is Tolerable in Treatment Naïve (TN) and Relapsed or Refractory (RR) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Patients Including Patients with High-Risk (HR) Disease: New and Updated Results of 116 Patients in a Phase Ib/II Study

3. Differences in Quality of Life Between Bendamustine Plus Rituximab Compared with Standard First-Line Treatments in Patients with Previously Untreated Advanced Indolent Non-Hodgkin’s Lymphoma or Mantle Cell Lymphoma

Names in bold are affiliated with US Oncology Research
4. Combinations of the Selective Phosphatidylinositol 3-Kinase-Delta (PI3Kδ) Inhibitor GS–1101 (CAL-101) with Rituximab and/or Bendamustine Are Tolerable and Highly Active in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL): Results From a Phase I Study

5. The Bruton’s Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Is Active and Tolerated in Relapsed Follicular Lymphoma

6. Ibrutinib Is an Irreversible Molecular Inhibitor of Interleukin-2 Inducible Kinase: Expanding Therapeutic Potential and Modulating a Th1 Selective Pressure in CD4 T-Cells

7. Long-Term Outcome of Ruxolitinib Treatment in Patients with Myelofibrosis: Durable Reductions in Spleen Volume, Improvements in Quality of Life, and Overall Survival Advantage in COMFORT-I

8. An Open-Label, Randomized Study of Bendamustine and Rituximab (BR) Compared with Rituximab, Cyclophosphamide, Vincristine, and Prednisone (R-CVP) or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in First-Line Treatment of Patients with Advanced Indolent Non-Hodgkin’s Lymphoma (NHL) or Mantle Cell Lymphoma (MCL): The Bright Study

Posters:

1. Phase 1b Study of TRU-016, an Anti-CD37 SMIP™ Protein, in Combination with Bendamustine Vs Bendamustine Alone in Relapsed Chronic Lymphocytic Leukemia

2. Integrated Analysis of Long-Term Safety in Patients with Chronic Immune Thrombocytopenia Treated with Romiplostim

3. Combinations of the Phosphatidylinositol 3-Kinase-Delta (PI3Kδ) Inhibitor Gs-1101 (CAL-101) with Rituximab and/or Bendamustine Are Tolerable and Highly Active in Previously Treated, Indolent Non-Hodgkin Lymphoma: Results From a Phase I Study

Names in bold are affiliated with US Oncology Research
4. Results of a Phase 1 Dose-Escalation Study of Once-Weekly MLN9708, an Investigational Proteasome Inhibitor, in Patients with Relapsed/Refractory Lymphoma

5. Variation in Health-Related Quality of Life by Line of Therapy of Patients with Chronic Lymphocytic Leukemia

6. A Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory CD30-Positive Non-Hodgkin Lymphomas: Interim Results

7. Relationship between chelation and clinical outcomes in 600 lower-risk MDS patients: registry analysis at 36 months

8. Phase 2 trial of Intracycle Sequential Ofatumumab and Lenalidomide for the Treatment of Relapsed and Refractory Chronic Lymphocytic Leukemia

Publication only:

1. Treatment with the Thrombopoietin Receptor (TPO-R) Agonist Eltrombopag in Thrombocytopenic Patients (Pts) with Advances Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukemia (AML) – Results of a Placebo-Controlled, Randomized Phase I/III Trial

2. Oral Ezatiostat HCl (Telintra), a Glutathione Analog Prodrug GSTP1-1 Inhibitor, for Treatment of Patients with Myeloid Growth Factor-Resistant Idiopathic Chronic Neutropenia (ICN)
Lyons R

3. Multiple Myeloma Care in the Community Setting by Utilizing Progressive Clinical Care Pathways
Dhillon V, Martincic D, Lee CM, Njuguna N, Schmick D, Nagle AK, Garman RL, Kaya H

Many clinical studies led by US Oncology Research affiliated physicians have been prominently featured at numerous conferences held around the world, including the annual congress for the European Society for Medical Oncology (ESMO), the annual meeting for the American Society for Clinical Oncology (ASCO) and the San Antonio Breast Cancer Symposium (SABCS). Those studies, along with 75 published investigator-initiated manuscripts, feature forward looking clinical research topics that are helping advance cancer care today and discover improved therapies for the cancer care of tomorrow.

About US Oncology Research
Supported by McKesson Specialty Health and The US Oncology Network, US Oncology Research draws from a network of experienced investigators and dedicated clinical staff who specialize in Phase I through Phase IV oncology clinical trials. US Oncology Research serves more than 85 practices in nearly 250 locations managing more than 225 active trials at any given time. Physicians in the research network have enrolled more than 53,000 patients in over 1,200 trials since inception in 1992 and have contributed
to the development of 43 cancer therapies approved by the FDA. For more information call (800) 482-6700, option 4 or visit www.usoncology.com/oncologists.

Media Contact:
Claire Crye
(281) 863-6783
Claire.Crye@McKesson.com

###